Annovis Bio Finalizes Phase III Study of Buntanetap in Early Parkinson’s Treatment, Awaits Topline Data
BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) has recently announced the completion of the last patient visit in its phase III study of buntanetap, a leading candidate for treating …
Annovis Bio Finalizes Phase III Study of Buntanetap in Early Parkinson’s Treatment, Awaits Topline Data Read More